BACKGROUND: The goal of this study was to compare the characteristics of breast cancers and survival rates in HRT users versus nonusers. METHODS: Data were analyzed for 1055 patients > or = 50 years of age who had definitive therapy for breast cancer from 1994 through 2002. RESULTS: There were 471 (45%) HRT users. The median age at diagnosis was 61.0 years for HRT users and 68.0 years for HRT nonusers (P < .001). HRT users more often had tumors that were <1 cm (P = .007), node negative (P = .033), and grade I (P = .016). HRT users had a decreased risk of death versus nonusers (hazard ratio = .438, 95% confidence limit = .263 to .729, P = .002). CONCLUSIONS: HRT users developed breast cancer at a younger age than nonusers; HRT use was associated with the development of biologically more favorable cancers than those that developed in nonusers; and overall and disease-free survival rates were higher in HRT users than nonusers.
BACKGROUND: The goal of this study was to compare the characteristics of breast cancers and survival rates in HRT users versus nonusers. METHODS: Data were analyzed for 1055 patients > or = 50 years of age who had definitive therapy for breast cancer from 1994 through 2002. RESULTS: There were 471 (45%) HRT users. The median age at diagnosis was 61.0 years for HRT users and 68.0 years for HRT nonusers (P < .001). HRT users more often had tumors that were <1 cm (P = .007), node negative (P = .033), and grade I (P = .016). HRT users had a decreased risk of death versus nonusers (hazard ratio = .438, 95% confidence limit = .263 to .729, P = .002). CONCLUSIONS: HRT users developed breast cancer at a younger age than nonusers; HRT use was associated with the development of biologically more favorable cancers than those that developed in nonusers; and overall and disease-free survival rates were higher in HRT users than nonusers.
Authors: Kerryn W Reding; David R Doody; Anne McTiernan; Li Hsu; Scott Davis; Janet R Daling; Peggy L Porter; Kathleen E Malone Journal: Breast Cancer Res Treat Date: 2010-09-29 Impact factor: 4.872
Authors: Mary Panjari; Robin Bell; Marijana Lijovic; Maria La China; Max Schwarz; Pamela Fradkin; Jo Bradbury; Helen Farrugia; Susan R Davis Journal: Horm Cancer Date: 2010-03-09 Impact factor: 3.869
Authors: Rowan T Chlebowski; Garnet L Anderson; Margery Gass; Dorothy S Lane; Aaron K Aragaki; Lewis H Kuller; JoAnn E Manson; Marcia L Stefanick; Judith Ockene; Gloria E Sarto; Karen C Johnson; Jean Wactawski-Wende; Peter M Ravdin; Robert Schenken; Susan L Hendrix; Aleksandar Rajkovic; Thomas E Rohan; Shagufta Yasmeen; Ross L Prentice Journal: JAMA Date: 2010-10-20 Impact factor: 56.272
Authors: J Jonklaas; G Nogueras-Gonzalez; M Munsell; D Litofsky; K B Ain; S T Bigos; J D Brierley; D S Cooper; B R Haugen; P W Ladenson; J Magner; J Robbins; D S Ross; M C Skarulis; D L Steward; H R Maxon; S I Sherman Journal: J Clin Endocrinol Metab Date: 2012-04-10 Impact factor: 5.958
Authors: Amy L Shafrir; Ana Babic; Rulla M Tamimi; Bernard A Rosner; Shelley S Tworoger; Kathryn L Terry Journal: Br J Cancer Date: 2016-10-04 Impact factor: 7.640